High-definition CpG methylation of novel genes in gastric carcinogenesis identified by next-generation sequencing.
New York City, United States. In Mod Pathol, Feb 2016
Overall, 13 genes had significantly increased CpG methylation in gastric cancer vs non-metaplastic mucosa (BRINP1, CDH11, CHFR, EPHA5, EPHA7, FGF2, FLI1, GALR1, HS3ST2, PDGFRA, SEZ6L, SGCE, and SNRPN).
Ligand-targeted theranostic nanomedicines against cancer.
Torino, Italy. In J Control Release, Feb 2016
These studies corroborate the notion that unique receptor proteins such as IL-11Rα, GRP78, EphA5, among others, are differentially overexpressed in tumors and present opportunities to deliver tumor-specific therapeutic drugs.
Mutations leading to constitutive active gp130/JAK1/STAT3 pathway.
Paris, France. In Cytokine Growth Factor Rev, Oct 2015
(1) 60% of IHCA show IL-6 signal transducer (IL6ST; gp130) mutations; (2) 10% harbor mutations of the Fyn-related kinase FRK; (3) 5% harbor mutations in STAT3; (4) 5% harbor somatic mutations in the GNAS complex locus; and (5) 1% of IHCA harbor mutations in the Janus kinase 1 (JAK1).
The role of dasatinib in the management of chronic myeloid leukemia.
Nanjing, China. In Drug Des Devel Ther, 2014
It potently inhibits BCR/ABL and SRC-family kinases (SRC, LCK, HCK, YES, FYN, FGR, BLK, LYN, FRK), as well as c-KIT, PDGFR-a and -b, and ephrin receptor kinase.
Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Salamanca, Spain. In Clin Cancer Res, 2011
Among the most sensitive dasatinib targets are ABL, the SRC family kinases (SRC, LCK, HCK, FYN, YES, FGR, BLK, LYN, and FRK), and the receptor tyrosine kinases c-KIT, platelet-derived growth factor receptor (PDGFR) α and β, discoidin domain receptor 1 (DDR1), c-FMS, and ephrin receptors.